Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit - Gilde Healthcare

Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit

September 8, 2015

Utrecht, The Netherlands and Palma de Mallorca, Spain – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M in a late stage Series C financing round. The company is focused on the development of SNF472, a promising drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing haemodialysis.
Gilde Healthcare invested alongside a syndicate of international investors.

With the proceeds from this financing round Sanifit will advance its lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis. SNF472 has shown significant efficacy data in more than 20 preclinical studies and excellent safety and tolerability data in a phase Ia clinical trial in healthy volunteers. SNF472 is currently concluding a phase Ib/IIa pharmacology study in haemodialysis patients.

ESRD patients treated with dialysis experience higher rates of serious cardiovascular adverse events  and  mortality  as  a  consequence  of  accelerated  progression  of  cardiovascular calcification. Half of the mortality in dialysis patients is from cardiovascular complications. Calciphylaxis is the most severe form of cardiovascular calcification. It is a devastating rare disease that affects up to 4% of dialysis patients and has an overall mortality rate of about 80%. There are approximately 2.5 million dialysis patients worldwide with no effective treatment for this medical condition. ESRD represents a market opportunity of over €2Bn.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, US) is a European fund manager specialized in fast growing private healthcare companies. Since 2001 Gilde Healthcare raised EUR 600M in dedicated funds across two business lines: Healthcare Technologies and Healthcare Services. The Gilde Healthcare Technology funds invest growth and later-stage capital in businesses active in digital health, medical technologies and therapeutics, both in Europe and the US. The Gilde Healthcare Services funds participate in lower mid-market service providers in the Benelux and Germany. For more information please visit www.gildehealthcare.com

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023